Long-term protection from a meningococcal vaccine
Part of Infections clinical trials.
This study checks whether the MenFive™ vaccine still protects against meningococcal disease more than five years after vaccination. It aims to see how long the immune response lasts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received the MenFive™ vaccine more than five years ago
- You must provide written permission (consent) to join the study
- You must not have had meningococcal disease since being vaccinated
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
This trial tests a new vaccine that helps protect against 6 types of meningococcal bacteria, which can cause serious infections like meningitis. It is for healthy people aged 2 to 59 years.
This study tests an experimental meningitis vaccine in healthy babies and toddlers to see how well it works and if it's safe. If your child is between 2 and 23 months old and in good health, they might be able to join.
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
This study checks how long antibodies from certain vaccines (polio, measles-mumps-rubella, and hepatitis A) last in the body, 5 years after they were given. It helps researchers understand if booster shots might be needed later.
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
Hear when a new Meningoccocal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.